Denali Therapeutics Inc Cash Flow Conversion Efficiency
Denali Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has a cash flow conversion efficiency ratio of -0.116x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-97.00 Million) by net assets ($835.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Denali Therapeutics Inc (2015–2025)
Cash flow conversion efficiency of Denali Therapeutics Inc from 2015 to 2025. This chart illustrates how Denali Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Denali Therapeutics Inc for real-time trading data and today's change.
Denali Therapeutics Inc Cash Flow Conversion Ratio Explained
Denali Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Denali Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Denali Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Denali Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
National Storage REIT
AU:NSR
|
0.018x |
|
Perfect World Co Ltd
SHE:002624
|
0.057x |
|
Xi an Bright Laser Tech Co Ltd
SHG:688333
|
0.022x |
|
Aperam SA
MC:APAM
|
0.042x |
|
Colbun
SN:COLBUN
|
0.021x |
|
AIR CHINA LTD H ADR/20
F:AD2B
|
N/A |
|
Bavarian Nordic
CO:BAVA
|
0.042x |
|
Anhui Great Wall Military Industry Co Ltd
SHG:601606
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Denali Therapeutics Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Denali Therapeutics Inc from 2015 to 2025. Review DNLI FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.01 Billion | $-412.60 Million | -0.407x | -43.94% |
| 2024-12-31 | $1.23 Billion | $-347.69 Million | -0.283x | +18.57% |
| 2023-12-31 | $1.03 Billion | $-357.99 Million | -0.347x | -47.92% |
| 2022-12-31 | $1.04 Billion | $-244.72 Million | -0.235x | -6.87% |
| 2021-12-31 | $962.29 Million | $-211.39 Million | -0.220x | -160.73% |
| 2020-12-31 | $1.15 Billion | $416.15 Million | 0.362x | +194.23% |
| 2019-12-31 | $394.89 Million | $-151.58 Million | -0.384x | -518.83% |
| 2018-12-31 | $546.85 Million | $50.12 Million | 0.092x | +155.70% |
| 2017-12-31 | $465.80 Million | $-76.64 Million | -0.165x | +42.13% |
| 2016-12-31 | $254.52 Million | $-72.36 Million | -0.284x | -129.53% |
| 2015-12-31 | $-15.63 Million | $-15.05 Million | 0.963x | -- |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 pr… Read more